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Abstract
Background: The intestinal microbiota plays an important role in immune development and homeostasis. A
disturbed microbiota during early infancy is associated with an increased risk of developing inflammatory and
allergic diseases later in life. The mechanisms underlying these effects are poorly understood but are likely to
involve alterations in microbial production of fermentation-derived metabolites, which have potent immune
modulating properties and are required for maintenance of healthy mucosal immune responses. Probiotics are
beneficial bacteria that have the capacity to alter the composition of bacterial species in the intestine that can in
turn influence the production of fermentation-derived metabolites. Principal among these metabolites are the
short-chain fatty acids butyrate and acetate that have potent anti-inflammatory activities important in regulating
immune function at the intestinal mucosal surface. Therefore strategies aimed at restoring the microbiota profile
may be effective in the prevention or treatment of allergic and inflammatory diseases.
Presentation of the hypothesis: Probiotic bacteria have diverse effects including altering microbiota composition,
regulating epithelial cell barrier function and modulating of immune responses. The precise molecular mechanisms
mediating these probiotic effects are not well understood. Short-chain fatty acids such as butyrate are a class of
histone deacetylase inhibitors important in the epigenetic control of host cell responses. It is hypothesized that the
biological function of probiotics may be a result of epigenetic modifications that may explain the wide range of
effects observed. Studies delineating the effects of probiotics on short-chain fatty acid production and the
epigenetic actions of short-chain fatty acids will assist in understanding the association between microbiota and
allergic or autoimmune disorders.
Testing the hypothesis: We propose that treatment with specific probiotic bacteria under in vivo conditions
would offer the ideal conditions to examine the microbiological, immunological and epigenetic mechanisms of
action. Advances in epigenetic technology now allow investigators to better understand the complex biological
properties of probiotics and their metabolites.
Implications of the hypothesis: Determining the precise mechanisms of probiotic action will lead to more
specific and efficacious therapeutic strategies in the prevention or treatment of chronic inflammatory conditions.
Background
T h ei n t e s t i n a lm i c r o b i o t ap l a y sac r i t i c a lr o l ei nt h e
establishment and maintenance of healthy immune
responses. Delayed colonisation of the infant gut with
commensal bacteria or alterations in the microbiota pro-
file are suggested to be strong risk factors for the devel-
opment of immune-mediated chronic disorders such as
allergic and autoimmune diseases. Mice raised in a
germ- free environment fail to develop oral tolerance
and have persistent Th2-dependent immune responses
[1]. This immune deviation can be corrected by recon-
stituting the microbiota with a single bacteria species,
but only if this occurs during the neonatal period. Simi-
larly, infants with allergic disease have reduced numbers
of beneficial Bifidobacteria species and increased num-
bers of pathogenic Clostridia and Staphylococci com-
pared to non-allergic infants [2-4]. Moreover, these
changes occur prior to the onset of allergy, suggesting a
causal relationship between microbiota and healthy
immune responses. These observations have led to the
idea that probiotic bacteria - which have the potential to
restore the intestinal microbiota balance - may be
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immune-mediated diseases.
Probiotics mediate their activity by a variety of
mechanisms including altering the microbiota composi-
tion, maintaining epithelial barrier function and modu-
lating mucosal and systemic immune responses [5].
Importantly, the effects of probiotic bacteria are species
and strain-specific, so it is imperative to select probiotic
bacteria with specific activities based upon known
in vitro or in vivo effects that are relevant to the clinical
context they will be applied to. Lactobacillus and Bifido-
bacteria species have been studied in greatest detail and
are the most commonly used in research studies [6]. In
particular, significant effort has been made in the exami-
nation of probiotic therapy for the prevention of allergic
disease. Several clinical trials have demonstrated that a
combined prenatal/early postnatal treatment has the
greatest impact on reducing allergy symptoms, indicat-
ing the importance of early life interventions [7-9]. Pre-
natal supplementation with the probiotic Lactobacillus
rhamnosus GG (LGG) was found to reduce the develop-
ment of atopic dermatitis in high-risk infants by 2 years
of age [7]. However, subsequent studies using the same
or different probiotics have not confirmed these results,
suggesting that there may be intrinsic differences
between the probiotic strains used and study popula-
tions, reflecting the complexity of these studies [10].
Treatment with probiotics induces a variety of immu-
nological effects on epithelial function, dendritic cells,
Treg and T-helper responses. Examples of these effects
include 1) enhanced epithelial barrier function via inter-
actions with Toll-like receptors (TLRs) and modulation
of epithelial cell signal transduction pathways that regu-
late cytokine production to promote anti-inflammatory
responses [11-13]; 2) induction of tolerogenic DCs pro-
ducing low IFNg and elevated IL-10 [14]; 3) induction
of Treg activity associated with increased TGF-b and
IL-10 secretion by PBMCs [15,16]; 4) modulation of
T helper responses [17]; 5) stimulation of IgA responses
to oral and parenteral vaccines [18-20] and 6) modula-
tion of immune factors within breast milk such as
TGF-b, soluble CD14 and total IgA [14,21]. Genetic
analysis of probiotic effects following treatment of
healthy adults with L. casei and L. rhamnosus revealed
upregulation of several key mucosal immune response
genes encoding IFN-g production and TLR3/9 expres-
sion while L. acidophilus was found to upregulate
immunoregulatory genes including IL-17B, IRAK2 as
well as several chemokines and cellular adhesion mole-
cules in duodenal biopsies using a novel transcriptome
analysis [22].
An important role for commensal (including probio-
tic) bacteria is the fermentation of dietary compounds
leading to production of short-chain fatty acid (SCFA)
metabolites. Several SCFAs are known to be produced
such as butyrate, acetate and propionate. Levels of
SCFA have been demonstrated to be reduced in inflam-
matory diseases, possibly as a result of an altered gut
microbiota. These SCFAs have an important protective
function in the intestine and exert anti-inflammatory
effects in a number of animal models. Intestinal epithe-
lial cells of germ-free mice had reduced SCFA receptor
expression which was normalized following reconstitu-
tion with normal gut bacteria [23]. The SCFA, butyrate,
also has an important role as an energy source for the
mucosa in predominantly anaerobic environments such
as the gastrointestinal tract as well as having other criti-
cal biological functions such as immune regulation [24].
Moreover, butyrate improves epithelial barrier integrity
by modulating the expression of certain tight junction
proteins such as cingulin, ZO proteins and occludin
[25,26]. These combined effects promote establishment
of a healthy microbiota and the development of a
healthy gastrointestinal lymphoid tissue. Studies invol-
ving SCFA treatment using butyrate and acetate have
yielded promising results, with amelioration of inflam-
matory lesions in mouse models of allergic airways dis-
ease and colitis [27]. This has led to the idea that
probiotic supplementation could restore SCFA levels by
modulating the microbial environment, representing a
novel therapeutic or preventative strategy for chronic
inflammatory diseases.
Probiotic metabolites such as butyrate are therefore an
important class of therapeutic compounds. These SCFAs
are also a well-known class of epigenetic drugs known as
histone deacetylase inhibitors (HDACi) that have a cen-
tral role as anti-cancer agents with strong anti-prolifera-
tive effects on tumour cells [28,29]. This activity of
SCFAs may explain the anti-inflammatory effects
observed for probiotic bacteria. Intriguingly, the principal
HDACi compound is butyric acid (sodium butyrate)
which inhibits most HDAC enzymes except class III and
class II HDACs 6 and 10 [30]. Butyrate is one of the
most potent HDACi in human colon cancer cell lines
suggesting an integral role as anti-inflammatory deriva-
tives of microbial fermentation in the colon [24]. Studies
using fecal fermentation supernatants were found to be
rich in butyrate and exhibited strong HDAC inhibitory
properties in several colon cancer cell lines [31]. The
HDACi activity of butyrate and propionate was asso-
ciated with blockade of DC development primarily
through the Na
+ coupled monocarboxylate transporter
Slc5a8 [32].
Given the role of bacterial species in the production of
SCFAs, probiotics may be considered as an alternative
approach for the prevention or treatment of chronic
inflammatory diseases. Evidence in support of this effect
by probiotics is limited. The butyric acid-producing
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novel probiotic used for the treatment of inflammatory
bowel disease (IBD) [33]. The levels of this bacterium is
lower in IBD and treatment of mice with F. prausnitzii
led to a shift in microbiota composition, reduced inflam-
matory cytokine levels such as IL-2, increased the anti-
inflammatory cytokine IL-10 and reduced colitis and
mortality, suggesting that butyrate and other related
metabolites may be critical in host protection [34]. The
anti-inflammatory effects of SCFA-producing probiotic
bacterium was further illustrated with Propionibacterium
freudenreichii, which was found to shift the extracellular
pH from 7.5 to 5.5 in the colon and was related to levels
of the SCFAs, acetate and propionate [35]. It is possible
that probiotic-derived SCFA metabolites such as buty-
rate produce HDACi effects that have multiple down-
stream effector functions on many target cells, including
those of the immune system.T h i so f f e r sap r o m i s i n g
intervention approach for the treatment of inflammatory
conditions such as allergy and gastrointestinal disease.
The exact mechanism(s) of action for probiotic bacteria
have yet to be fully understood; therefore the
epigenomic-modifying capacity of probiotics will be
important in understanding how they mediate their
health-promoting effects.
Presentation of the hypothesis
Probiotics mediate pleiotropic effects however the pre-
cise mechanism(s) have yet to be fully elucidated. The
‘epigenome targeting’ hypothesis contends that the activ-
ity of probiotics and their metabolites are associated
with chromatin remodeling as a function of intrinsic
histone deacetylase inhibition. Modulation of gene tran-
scription is an essential component of many biological
processes. The onset of pathological conditions such as
cancer and chronic inflammation often result from aber-
rant gene transcription. Integral to this process are epi-
genetic factors involving two critical enzymes, histone
acetylases (HATs) and histone deacetylases (HDACs).
These produce post-translational modifications of his-
tone proteins and result in changes to chromatin struc-
ture and function [36,37]. While HATs serve to
acetylate histones, conferring a ‘relaxed’ chromatin
structure that allows transcriptional activation, HDACs
has the opposite effect. HDAC enzymes repress tran-
scription through tightening of the chromatin structure,
excluding accessibility of transcription factors and other
regulatory proteins to DNA and therefore the ability to
influence gene expression [38].
The recent advances in understanding epigenetic pro-
cesses in the maintenance of health allows us to investi-
gate more precisely the mechanisms of action of novel
t h e r a p i e ss u c ha sp r o b i o t i c si n defined clinical contexts.
Critical transcriptional regulators of inflammation such as
NF-B and Foxp3 can now be studied closely to determine
the impact of dietary/probiotic supplementation. The evi-
dence presented above and our hypothesis provide for the
first time a direct link between the anti-inflammatory and
immunoregulatory properties observed for probiotics in
terms of Treg induction, DC maturation and cytokine/
chemokine secretion and the molecular events involved at
the epigenetic level. We believe that the biological activity
of probiotics are mediated through complex epigenetic
changes that regulate the activation status of key transcrip-
tion factors involved in host immunity.
Testing the hypothesis
Testing this hypothesis should be undertaken in an in
vivo system such as the mouse, or preferably in humans
using a randomized, double-blind, placebo-controlled
s t u d yd e s i g n .P r o b i o t i cb a c t e r i ao rp l a c e b os h o u l db e
given prenatally and/or post-natally to infants at high-
risk of developing allergic disease. Clinical effects of the
probiotic should be assessed by doctor-diagnosed allergy
using defined criteria, skin prick test positivity, and
SCORAD analysis of eczema severity. Immunological
outcomes can be assessed by enumerating Treg and DC
populations and the profile of cytokine secretion by cul-
tured cord and peripheral blood mononuclear cells in
response to SCFA metabolites. Levels of SCFA can be
measured in stool or blood. Correlation between immu-
nological and epigenetic changes could be assessed in
the first instance by simple immunoblot analysis for
histone hyperacetylation as well as real-time PCR for spe-
cific immune gene regulation in relevant cells. Genome-
wide sequencing techniques such as mRNA-Seq (gene
expression) and ChIP-Seq (specific epigenetic modifica-
tions including acetylation) will further our understand-
ing of the critical biological functions of probiotics.
Implications of the hypothesis
Interest in probiotics has intensified in recent years due to
their potential health benefits and as treatments for a wide
range of inflammatory and immunological conditions.
Probiotic bacteria have been demonstrated to modulate a
variety of microbiological and immunological parameters
although the precise mechanisms for these effects are yet
to be fully elucidated. The ability of probiotics to alter
intestinal microbiota composition and diversity suggest an
important role for SCFAs such as butyrate. The demon-
stration of beneficial probiotic effects through as yet uni-
dentified epigenetic mechanisms will have significant
implications in the prevention and/or treatment of allergy
and other chronic inflammatory diseases.
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